Measuring Progress in Neglected Disease Drug Development-Reference-Cited by-同舟云学术

Measuring Progress in Neglected Disease Drug Development

Published:2014-07 Issue:7 Volume:36 Page:1037-1042
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Cohen Joshua P.,Sturgeon Greg,Cohen Alisa

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Editorial: drug development for neglected diseases: a public health challenge;Fehr;Trop Med Int Health,2006

2. Global Funding of Innovation for Neglected Diseases: G-FINDER Report. http://www.policycures.org/downloads/g-finder%20summary%202011.pdf. Accessed May 5, 2013.

3. Drug development for neglected diseases: a deficient market and a public-health policy failure;Trouiller;Lancet,2002

4. Development of and access to products for neglected diseases;Cohen;PLoS One,2010

5. Global public-private partnerships: Part I—a new development in health?;Buse;Bull World Health Organ,2000

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis;BMJ Open;2024-03

2. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019;2023-06-04

3. Product Development Partnerships: Collaborative Multi-sector Regimes to Accelerate Vaccine Development;Global Encyclopedia of Public Administration, Public Policy, and Governance;2022

4. Mulberrin inhibits Botrytis cinerea for strawberry storage by interfering with the bioactivity of 14α-demethylase (CYP51);Food & Function;2022

5. Computational identification of chemical compounds with potential anti-Chagas activity using a classification tree;SAR and QSAR in Environmental Research;2021-01-02